Search

Your search keyword '"Cassiman, David"' showing total 220 results

Search Constraints

Start Over You searched for: Author "Cassiman, David" Remove constraint Author: "Cassiman, David" Database Unpaywall Remove constraint Database: Unpaywall
220 results on '"Cassiman, David"'

Search Results

4. Tacrolimus Drug Exposure Level and Smoking Are Modifiable Risk Factors for Early De Novo Malignancy After Liver Transplantation for Alcohol-Related Liver Disease

5. Brain function in classic galactosemia, a galactosemia network (GalNet) members review

6. Aberrant N-glycosylation in pathogenic variants of adenosine deaminase 2 underlying human ADA2 deficiency

8. Tracer metabolomics reveals the role of aldose reductase in glycosylation

9. Distinct immunometabolic signatures in circulating immune cells define disease outcomes in acute-on-chronic liver failure

10. Sequential BAVENO VI plus dedicated spleen stiffness measurement or a novel spleen-centered algorithm significantly enlarges non-invasive ruling out of high risk varices: results from an international derivation-validation cohort study

12. Data from Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth

13. Data from Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth

14. Supplementary Information from Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth

15. Supplementary Information from Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth

20. Utility and prognostic value of diagnosing MAFLD in patients undergoing liver transplantation for alcohol‐related liver disease

22. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial

23. PPARγ lipodystrophy mutants reveal intermolecular interactions required for enhancer activation

24. EXPLORE B: A prospective, long‐term natural history study of patients with acute hepatic porphyria with chronic symptoms

25. Pyruvate and uridine rescue the metabolic profile of OXPHOS dysfunction

29. Uncovering monocyte transcription, functional and metabolic signatures in recovery and non-recovery ACLF patients

30. Clinical utility of non-ceruloplasmin copper determined by copper speciation for monitoring Wilson disease therapy: comparative data analysis with 24-hour urinary copper excretion from the CHELATE trial

31. Neurocognitive outcome and mental health in children with tyrosinemia type 1 and phenylketonuria: A comparison between two genetic disorders affecting the same metabolic pathway

39. Overlapping and divergent hepatic and lipoprotein phenotypes in untreated adults with acid sphingomyelinase deficiency versus untreated adults with Gaucher disease from two pivotal clinical trials

40. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study

41. Correction to: An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

43. Sorbitol Is a Severity Biomarker for PMM2‐CDG with Therapeutic Implications

44. Genotype-Phenotype Correlations in PMM2-CDG

47. Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease

48. Uncertain Diagnosis of Fabry Disease in Patients with Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up

Catalog

Books, media, physical & digital resources